BCRX  Biocryst Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.29 (+2.20%)

Stability Price

Overvalued by 98.62%

Company Metrics

  • 0 P/E
  • 53.01 P/S
  • 10.52 P/B
  • -0.638 EPS
  • -118.77% Cash ROIC
  • 2.49 Cash Ratio
  • 0 / 0% Dividend
  • 1.28M Avg. Vol.
  • 968.7M Market Cap.

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Hope For Ebola Cure
Bidness ETC - 7 hours ago
BioCryst Pharmaceuticals Inc. (BCRX) announced yesterday it will begin trials for its experimental Ebola drug in a few weeks.
BioCryst to Launch NHP Ebola Drug Safety, Efficacy Studies 'Within Weeks' - Forbes
BioCryst Receives Additional NIAID Funding to Conduct a Non-Human Primate ... - Wall Street Journal
Momentum Indicators for Biotech Stocks -- Exact Sciences, BioCryst Pharma ...
MarketWatch - Aug 25, 2014
Investor-Edge has initiated coverage on the following equities: Exact Sciences Corporation EXAS, +4.06% BioCryst Pharmaceuticals Inc. BCRX, +2.89% Spectrum Pharmaceuticals Inc. SPPI, +1.01% Aeterna Zentaris Inc. AEZS, +0.00% and CTI BioPharma ...
Can BioCryst Pharmaceuticals, Inc. (BCRX) Stop The Ebola Outbreak?
ETF Daily News (blog) - Aug 5, 2014
biotechnology Jay Taylor: I grew up in Reston, Virginia. Unless you're from the Washington D.C. area I doubt you've ever heard of it.
Biocryst Pharmaceuticals (BCRX) Highlighted As Today's Perilous Reversal Stock - TheStreet.com
Stocks On the Move: BioCryst Pharmaceuticals, Inc., ITT Educational Services ... - Schaeffers Research (blog)
BioCryst Pharma Inc (BCRX) Coverage Initiated By JP Morgan With Overweight
Wall Street Pit - Aug 8, 2014
BioCryst Pharmaceuticals, Inc. (BCRX) was initiated with a 'Overweight' and it was given a $20.00 price target at JP Morgan (JPM) in a research report issued to clients on Friday.
Notable Analyst Actions: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ... - Financial Wired
Friday's Hot Stocks: Mercadolibre Inc (MELI), BioCryst Pharmaceuticals, Inc ... - Investor Wired
Should Investors Really Be Chasing Potential Ebola Treatments?
24/7 Wall St. - Aug 4, 2014
Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR) and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) are two such companies with studies taking place that could treat Ebola.
As Ebola virus spreads, investors bet on potential cures - The Gazette: Eastern Iowa Breaking News and Headlines
Ebola Drug by Tekmira May Be Used on Infected Patients - Bloomberg
Watch List: BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX), ARMOUR ...
Market News Call - Aug 29, 2014
The company on Aug. 29 announced that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded a contract modification for an additional $2.4 million to BioCryst to conduct a dose ranging efficacy study of an intramuscular ...
BioCryst Pharmaceuticals CFO Thomas R. Staab II Sells 10000 Shares (BCRX)
Intercooler - Aug 29, 2014
BioCryst Pharmaceuticals logo BioCryst Pharmaceuticals (NASDAQ:BCRX) CFO Thomas R. Staab II unloaded 10,000 shares of the company's stock on the open market in a transaction that occurred on Wednesday, August 27th. The shares were sold at an ...
Insider Selling: Thomas R. Staab II Sells 10000 Shares of BioCryst ... - WKRB News
Stocks in News: Google Inc (NASDAQ:GOOGL), 22nd Century Group Inc ... - Financial Wired (registration)
BioCryst Pharmaceuticals (BCRX) Edging Higher on Additional NIAID Funding
Wall Street Pit - Aug 13, 2014
BioCryst Pharmaceuticals, Inc. (BCRX) shares are edging higher in early trading on Wednesday following news that $4.1 million additional National Institute of Allergy and Infectious Diseases [NIAID] funding will be given to the company to advance ...
US government advances development of BioCryst's potential Ebola drug - Reuters UK
BioCryst Receives Additional NIAID Funding to Advance Development of ... - CNNMoney
BioCryst Pharmaceuticals Receives Consensus Rating of "Buy" from Analysts ...
WKRB News - Aug 22, 2014
BioCryst Pharmaceuticals logo BioCryst Pharmaceuticals (NASDAQ:BCRX) has earned a consensus rating of “Buy” from the twelve brokerages that are covering the company, Stock Ratings Network reports. Two research analysts have rated the stock with a ...
WHO Offers Update on Ebola Outbreak for Aug. 17 - 18 (TKMR) (BCRX) (NLNK) - StreetInsider.com (subscription)
Trader's Buzzers - BioCryst Pharmaceuticals, Inc. (BCRX), Uranium Energy Corp ...
Techsonian (press release) - Aug 25, 2014
Birmingham, West Midlands - (TechSonian) - 25 August 2014 - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised additional options to conduct Phase 1 clinical ...